Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...
3d
MarketBeat on MSNModerna: 4 Key Reasons the CEO Just Bought $5M in SharesCompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.
Short sellers increased their bets against the broader healthcare sector in February vs. January, and Moderna remained the ...
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté ...
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...
Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...
Wall Street rebondit grâce à l'exemption de droits de douane sur les véhicules La Bourse de New York a terminé en hausse ...
Insider Monkey on MSN9d
Why Moderna (MRNA) Stock Is Rallying TodayModerna's CEO Buys MRNA Stock Last night, two purchases of Moderna's stock by a firm controlled by MRNA CEO Stephane Bancel ...
(AOF) - Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté pour 6 millions de dollars d’actions de la société.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results